Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.
Inflation Reduction Act’s $35 insulin cap linked to rise in prescription fills
The Inflation Reduction Act’s policy capping out-of-pocket costs for insulin to $35 for a month’s supply led to increases in the total number of insulin
July 25, 2023